Information Provided By:
Fly News Breaks for August 8, 2017
NUVA
Aug 8, 2017 | 05:44 EDT
Piper Jaffray analyst Matt O'Brien views the 23% pullback in shares of NuVasive since the company's Q2 results as overdone. The analyst recommends investors start building positions in the name. The analyst continues to expect the pure play spine names to "out innovate and continue to take share from the two main large incumbents." He keeps an Overweight rating on NuVasive with a $90 price target.
News For NUVA From the Last 2 Days
There are no results for your query NUVA